Close Menu

lung cancer

Papers of Note

Premium

Sequencing-Related Papers of Note, Feb. 2009

The firm published data from a study showing that the same biomarker used in its miRNA-based test for squamous lung cancer provided 96 percent sensitivity.

The hospital will use a new lab to study tumors and to try to develop individual treatments.

In its annual report, Exiqon also indicated that it would eventually seek US Food and Drug Administration approval for its miRNA diagnostics so that they could be made available to a broader range of laboratories and pathologists.

The company last month presented data showing that the test could be used to detect cancer, but more work is needed to refine the test so that it can distinguish between different types of malignancies.

The data presented last week at the Molecular Medicine Tri-Conference showed that the investigational test detected "dramatically different" miRNA expression patterns in the blood of cancer patients compared to those who were cancer-free.

Ballast Point Ventures made an equity investment in the pharmacogenomics company.

Pages

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.